Cluenex
Log inStart free
All stocks · Healthcare · Health Care Equipment

Abbott Laboratories ABT

Abbott Laboratories scores average on business quality (5.5 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$99.60Oct 10, 2026
Business qualityAverage
Next earningsOct 21, 2026, before the open
Insiders, 90 daysSelling

Why it matters

  1. What Abbott Laboratories does

    Abbott Laboratories makes money by selling medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals globally to hospitals, laboratories, and patients. The company is leaning into its core medical device portfolio to sustain cash generation against steady macroeconomic shifts.

  2. What it does best

    Abbott dominates continuous glucose monitoring through its FreeStyle Libre ecosystem, backed by a gross margin of 56.8%. High patient switching costs and embedded hospital workflow integration protect this franchise from rapid displacement.

  3. The main risk

    Execution delays in rolling out next-generation diagnostic platforms threaten its volume growth, which sits in the bottom third of its sector at the 34th percentile.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityFair

Operating margin stands at 17.1% with an FCF margin near 16.8%. Profitability is stable, though gross margins trail high-end peers due to its diversified nutritional and generic drug mix.

MoatFair

Switching costs across medical devices and diagnostics lock in healthcare providers and patients. Its operating margin sector percentile of 52 reflects a middle-of-the-pack competitive moat.

GrowthSlow

Revenue growth registers at 5.7%, showing steady performance but lagging behind historical peaks. Growth is supported by the medical device segment as post-pandemic normalization stabilizes.

Financial healthStrong

Debt-to-equity sits at 0.25 with interest coverage at 10.4x, making debt service manageable. Free cash flow reached $7.8B, pointing to steady capital generation and a strong balance sheet.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

3 sold $46.9M outside pre-planned sales.

Our sealed record on ABT

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is ABT a good business?

Abbott Laboratories scores average on the Cluenex quality check (5.5 of 10), measured against its own industry. Profitability is fair, moat fair, growth slow and financial health strong.

Are insiders buying ABT?

In the last 90 days of SEC Form 4 filings: 3 sold $46.9M outside pre-planned sales.

When does ABT report earnings?

Oct 21, 2026, before the open.

For members

See ABT today

  • Today's verdict on ABT, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Abbott Laboratories (ABT)”, https://cluenex.com/stocks/abt/, data as of Oct 10, 2026.